![]()
|
|
||||||||
J. Biol. Chem., Vol. 282, Issue 7, 4894-4907, February 16, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
1
2
From the
Laboratory of Biochemistry and Vascular Biology, Division of Hematology, and the
Laboratory of Biophysics, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, and ¶Membrane Biophysics Section, Laboratory of Computational Biology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892
Hydrogen peroxide (H2O2) triggers a redox cycle between ferric and ferryl hemoglobin (Hb) leading to the formation of a transient protein radical and a covalent hemeprotein cross-link. Addition of H2O2 to highly purified human hemoglobin (HbA0) induced structural changes that primarily resided within
subunits followed by the internalization of the heme moiety within
subunits. These modifications were observed when an equal molar concentration of H2O2 was added to HbA0 yet became more abundant with greater concentrations of H2O2. Mass spectrometric and amino acid analysis revealed for the first time that
Cys-93 and
Cys-112 were oxidized extensively and irreversibly to cysteic acid when HbA0 was treated with H2O2. Oxidation of further amino acids in HbA0 exclusive to the
-globin chain included modification of
Trp-15 to oxyindolyl and kynureninyl products as well as
Met-55 to methionine sulfoxide. These findings may therefore explain the premature collapse of the
subunits as a result of the H2O2 attack. Analysis of a tryptic digest of the main reversed phase-high pressure liquid chromatography fraction revealed two
-peptide fragments (
128 -
139) and a heme moiety with the loss of iron, cross-linked between
Ser-138 and the porphyrin ring. The novel oxidative pathway of HbA0 modification detailed here may explain the diverse oxidative, toxic, and potentially immunogenic effects associated with the release of hemoglobin from red blood cells during hemolytic diseases and/or when cell-free Hb is used as a blood substitute.
Received for publication, October 24, 2006 , and in revised form, December 15, 2006.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bldg. 29, Rm. 112, Bethesda, MD 20892. Tel.: 301-827-3813; E-mail: abdu.alayash{at}fda.hhs.gov.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |